Committee Action
On February 29, 2024, the Subcommittee on Health held a
hearing on several bills, including H.R. 3433, as well as H.R.
7384 and H.R. 7383, which are included with slight modification
in the amended text of H.R. 3433. The title of the hearing was
``Legislative Proposals to Support Patients with Rare
Diseases.'' The Subcommittee received testimony from:
Terence Flotte, MD, Provost and Dean of
UMass Chan Medical School, Vice President of American
Society of Gene and Cell Therapy;
Alexander Bassuk, MD, PhD, Physician-in-
Chief, University of Iowa Stead Family Children's
Hospital; Chair and Professor, Stead Family Department
of Pediatrics;
Aaron Kesselheim, MD, JD, MPH, Professor of
Medicine, Harvard Medical School; Director, Program On
Regulation, Therapeutics, And Law (PORTAL) at Brigham
and Women's Hospital;
Jeromie Ballreich, PhD, Associate Research
Professor, Johns Hopkins Bloomberg School of Public
Health;
Alice Chen, PhD, Senior Fellow, USC
Schaeffer Center for Health Policy and Economics;
Associate Professor and Vice Dean for Research, USC Sol
Price School of Public Policy; and,
Khrystal Davis, JD, Founding President,
Texas Rare Alliance.
On May 16, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 3433, as amended, to the full
Committee by a vote of 16 yeas and 11 nays.
On September 18, 2024, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 3433, as
amended, favorably reported to the House by a recorded vote of
43 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to promote
the development of new and effective treatments for pediatric
cancer and rare pediatric diseases.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 3433 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 3433:
On February 29, 2024, the Subcommittee on
Health held a hearing on H.R. 3433, as well as H.R.
7384 and H.R. 7383, which are included with slight
modification in the amended text of H.R. 3433. The
title of the hearing was ``Legislative Proposals to
Support Patients with Rare diseases.'' The Subcommittee
received testimony from:
Terence Flotte, MD, Provost and Dean of
UMass Chan Medical School, Vice President of American
Society of Gene and Cell Therapy;
Alexander Bassuk, MD, PhD, Physician-in-
Chief, University of Iowa Stead Family Children's
Hospital; Chair and Professor, Stead Family Department
of Pediatrics;
Aaron Kesselheim, MD, JD, MPH, Professor
of Medicine, Harvard Medical School; Director, Program
On Regulation, Therapeutics, And Law (PORTAL) at
Brigham and Women's Hospital;
Jeromie Ballreich, PhD, Associate
Research Professor, Johns Hopkins Bloomberg School of
Public Health;
Alice Chen, PhD, Senior Fellow, USC
Schaeffer Center for Health Policy and Economics;
Associate Professor and Vice Dean for Research, USC Sol
Price School of Public Policy; and,
Khrystal Davis, JD, Founding President,
Texas Rare Alliance.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 3433 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the ``Give
Kids a Chance Act of 2024''.
TITLE I--GIVE KIDS A CHANCE
Section 101. Research into pediatric uses of drugs; additional
authorities of Food and Drug Administration regarding
molecularly targeted cancer drugs
Section 101 provides the Food and Drug Administration (FDA)
the authority to require pediatric cancer trials for new drugs
that are used in combination with active ingredients that meet
the standard of care for targeting pediatric cancer or have
been approved to treat adult cancer and are directed at
molecular targets for pediatric cancer. It would also require
the Government Accountability Office to conduct a study and
report to Congress on the effectiveness of the requirements
outlined in this section in the development of drugs and
biological products for pediatric cancer indications.
Section 102. Ensuring completion of pediatric study requirements
Section 102 provides the FDA the authority to enforce
against companies that fail to meet pediatric study
requirements. The Secretary of the Department of Health and
Human Services shall perform due diligence before concluding
failure to meet requirements.
Section 103. FDA report on PREA enforcement
Section 103 requires the FDA to report on enforcement of
the Pediatric Research Equity Act (PREA).
Section 104. Extension of authority to issue priority review vouchers
to encourage treatments for rare pediatric diseases
Section 104 extends the FDA priority review voucher program
from fiscal year 2024 through fiscal year 2029, to incentivize
the development of drugs for rare pediatric diseases. It also
requires a study from the Government Accountability Office on
the effectiveness of the pediatric PRV program.
Section 105. Limitations on exclusive approval or licensure of orphan
drugs
Section 105 introduced as H.R. 7383, the ``Retaining Access
and Restoring Exclusivity (RARE) Act,'' by Rep. Doris Matsui
(D-CA), clarifies that orphan drug exclusivity applies to the
approved indication, rather than the potentially broader
designation, in alignment with the FDA's interpretation.
Section 106. Program for pediatric studies of drugs
Section 106 updates authority for the National Institutes
of Health (NIH) to fund studies of drugs in children, to better
reflect how it is currently funded.
TITLE II--UNITED STATES-ABRAHAM ACCORDS COOPERATION AND SECURITY
Section 201. Establishment of Abraham Accords office within Food and
Drug Administration
Section 201 would require the Food and Drug Administration
to establish an office in an Abraham Accords country to enhance
facilitation with the agency and require the Secretary of
Health and Human Services to submit a report to Congress 3
years after the date of enactment of this Act to evaluate the
office's progress.
TITLE III--ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK
Section 301. Registration fees
Section 301 allows the Secretary of Health and Human
Services to collect registration fees from any member of the
Organ Procurement Transplantation Network (OPTN) for each
transplant candidate such member places on the list and
distribute these fees to support the operation of OPTN.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
FEDERAL FOOD, DRUG, AND COSMETIC ACT
* * * * * * *
CHAPTER III--PROHIBITED ACTS AND PENALTIES
* * * * * * *
penalties
Sec. 303. (a)(1) Any person who violates a provision of
section 301 shall be imprisoned for not more than one year or
fined not more than $1,000, or both.
(2) Notwithstanding the provisions of paragraph (1) of this
section, if any person commits such a violation after a
conviction of him under this section has become final, or
commits such a violation with the intent to defraud or mislead,
such person shall be imprisoned for not more than three years
or fined not more than $10,000 or both.
(b)(1) Notwithstanding subsection (a), any person who
violates section 301(t) by--
(A) knowingly importing a drug in violation of
section 801(d)(1),
(B) knowingly selling, purchasing, or trading a drug
or drug sample or knowingly offering to sell, purchase,
or trade a drug or drug sample, in violation of section
503(c)(1),
(C) knowingly selling, purchasing, or trading a
coupon, knowingly offering to sell, purchase, or trade
such a coupon, or knowingly counterfeiting such a
coupon, in violation of section 503(c)(2), or
(D) knowingly distributing drugs in violation of
section 503(e)(1),
shall be imprisoned for not more than 10 years or fined not
more than $250,000, or both.
(2) Any manufacturer or distributor who distributes drug
samples by means other than the mail or common carrier whose
representative, during the course of the representative's
employment or association with that manufacturer or
distributor, violated section 301(t) because of a violation of
section 503(c)(1) or violated any State law prohibiting the
sale, purchase, or trade of a drug sample subject to section
503(b) or the offer to sell, purchase, or trade such a drug
sample shall, upon conviction of the representative for such
violation, be subject to the following civil penalties:
(A) A civil penalty of not more than $50,000 for each
of the first two such violations resulting in a
conviction of any representative of the manufacturer or
distributor in any 10-year period.
(B) A civil penalty of not more than $1,000,000 for
each violation resulting in a conviction of any
representative after the second conviction in any 10-
year period.
For the purposes of this paragraph, multiple convictions of one
or more persons arising out of the same event or transaction,
or a related series of events or transactions, shall be
considered as one violation.
(3) Any manufacturer or distributor who violates section
301(t) because of a failure to make a report required by
section 503(d)(3)(E) shall be subject to a civil penalty of not
more than $100,000.
(4)(A) If a manufacturer or distributor or any representative
of such manufacturer or distributor provides information
leading to the institution of a criminal proceeding against,
and conviction of, any representative of that manufacturer or
distributor for a violation of section 301(t) because of a
sale, purchase, or trade or offer to purchase, sell, or trade a
drug sample in violation of section 503(c)(1) or for a
violation of State law prohibiting the sale, purchase, or trade
or offer to sell, purchase, or trade a drug sample, the
conviction of such representative shall not be considered as a
violation for purposes of paragraph (2).
(B) If, in an action brought under paragraph (2) against a
manufacturer or distributor relating to the conviction of a
representative of such manufacturer or distributor for the
sale, purchase, or trade of a drug or the offer to sell,
purchase, or trade a drug, it is shown, by clear and convincing
evidence--
(i) that the manufacturer or distributor conducted,
before the institution of a criminal proceeding against
such representative for the violation which resulted in
such conviction, an investigation of events or
transactions which would have led to the reporting of
information leading to the institution of a criminal
proceeding against, and conviction of, such
representative for such purchase, sale, or trade or
offer to purchase, sell, or trade, or
(ii) that, except in the case of the conviction of a
representative employed in a supervisory function,
despite diligent implementation by the manufacturer or
distributor of an independent audit and security system
designed to detect such a violation, the manufacturer
or distributor could not reasonably have been expected
to have detected such violation,
the conviction of such representative shall not be considered
as a conviction for purposes of paragraph (2).
(5) If a person provides information leading to the
institution of a criminal proceeding against, and conviction
of, a person for a violation of section 301(t) because of the
sale, purchase, or trade of a drug sample or the offer to sell,
purchase, or trade a drug sample in violation of section
503(c)(1), such person shall be entitled to one-half of the
criminal fine imposed and collected for such violation but not
more than $125,000.
(6) Notwithstanding subsection (a), any person who is a
manufacturer or importer of a prescription drug under section
804(b) and knowingly fails to comply with a requirement of
section 804(e) that is applicable to such manufacturer or
importer, respectively, shall be imprisoned for not more than
10 years or fined not more than $250,000, or both.
(7) Notwithstanding subsection (a)(2), any person that
knowingly and intentionally adulterates a drug such that the
drug is adulterated under subsection (a)(1), (b), (c), or (d)
of section 501 and has a reasonable probability of causing
serious adverse health consequences or death to humans or
animals shall be imprisoned for not more than 20 years or fined
not more than $1,000,000, or both.
(8) Notwithstanding subsection (a), any person who violates
section 301(i)(3) by knowingly making, selling or dispensing,
or holding for sale or dispensing, a counterfeit drug, or who
violates section 301(fff)(3) by knowingly making, selling or
dispensing, or holding for sale or dispensing, a counterfeit
device, shall be imprisoned for not more than 10 years or fined
in accordance with title 18, United States Code, or both.
(c) No person shall be subject to the penalties of subsection
(a)(1) of this section, (1) for having received in interstate
commerce any article and delivered it or proffered delivery of
it, if such delivery or proffer was made in good faith, unless
he refuses to furnish on request of an officer or employee duly
designated by the Secretary the name and address of the person
from whom he purchased or received such article and copies of
all documents, if any there be, pertaining to the delivery of
the article to him; or (2) for having violated section 301(a)
or (d), if he establishes a guaranty or undertaking signed by,
and containing the name and address of, the person residing in
the United States from whom he received in good faith the
article, to the effect, in case of an alleged violation of
section 301(a), that such article is not adulterated or
misbranded, within the meaning of this Act, designating this
Act, or to the effect, in case of an alleged violation of
section 301(d), that such article is not an article which may
not, under the provisions of section 404 or 505, be introduced
into interstate commerce; or (3) for having violated section
301(a), where the violation exists because the article is
adulterated by reason of containing a color additive not from a
batch certified in accordance with regulations promulgated by
the Secretary under this Act, if such person establishes a
guaranty or undertaking signed by, and containing the name and
address of, the manufacturer of the color additive, to the
effect that such color additive was from a batch certified in
accordance with the applicable regulations promulgated by the
Secretary under this Act; or (4) for having violated section
301 (b), (c), or (k) by failure to comply with section 502(f)
in respect to an article received in interstate commerce to
which neither section 503(a) nor section 503(b)(1) is
applicable, if the delivery or proffered delivery was made in
good faith and the labeling at the time thereof contained the
same directions for use and warning statements as were
contained in the labeling at the time of such receipt of such
article; or (5) for having violated section 301(i)(2) if such
person acted in good faith and had no reason to believe that
use of the punch, die, plate, stone, or other thing involved
would result in a drug being a counterfeit drug, or for having
violated section 301(i)(3) if the person doing the act or
causing it to be done acted in good faith and had no reason to
believe that the drug was a counterfeit drug; or (6) for having
violated section 301(fff)(2) if such person acted in good faith
and had no reason to believe that use of the punch, die, plate,
stone, or other thing involved would result in a device being a
counterfeit device, or for having violated section 301(fff)(3)
if the person doing the act or causing it to be done acted in
good faith and had no reason to believe that the device was a
counterfeit device.
(d) No person shall be subject to the penalties of subsection
(a)(1) of this section for a violation of section 301 involving
misbranded food if the violation exists solely because the food
is misbranded under section 403(a)(2) because of its
advertising.
(e)(1) Except as provided in paragraph (2), whoever knowingly
distributes, or possesses with intent to distribute, human
growth hormone for any use in humans other than the treatment
of a disease or other recognized medical condition, where such
use has been authorized by the Secretary of Health and Human
Services under section 505 and pursuant to the order of a
physician, is guilty of an offense punishable by not more than
5 years in prison, such fines as are authorized by title 18,
United States Code, or both.
(2) Whoever commits any offense set forth in paragraph (1)
and such offense involves an individual under 18 years of age
is punishable by not more than 10 years imprisonment, such
fines as are authorized by title 18, United States Code, or
both.
(3) Any conviction for a violation of paragraphs (1) and (2)
of this subsection shall be considered a felony violation of
the Controlled Substances Act for the purposes of forfeiture
under section 413 of such Act.
(4) As used in this subsection the term ``human growth
hormone'' means somatrem, somatropin, or an analogue of either
of them.
(5) The Drug Enforcement Administration is authorized to
investigate offenses punishable by this subsection.
(f)(1)(A) Except as provided in subparagraph (B), any person
who violates a requirement of this Act which relates to devices
shall be liable to the United States for a civil penalty in an
amount not to exceed $15,000 for each such violation, and not
to exceed $1,000,000 for all such violations adjudicated in a
single proceeding. For purposes of the preceding sentence, a
person accredited under paragraph (2) of section 704(g) who is
substantially not in compliance with the standards of
accreditation under such section, or who poses a threat to
public health or fails to act in a manner that is consistent
with the purposes of such section, shall be considered to have
violated a requirement of this Act that relates to devices.
(B) Subparagraph (A) shall not apply--
(i) to any person who violates the requirements of
section 519(a) or 520(f) unless such violation
constitutes (I) a significant or knowing departure from
such requirements, or (II) a risk to public health,
(ii) to any person who commits minor violations of
section 519(e) or 519(g) (only wit